Company Description
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.
Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Country | United States |
Founded | 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 48 |
CEO | Timothy Lu |
Contact Details
Address: 2 Corporate Drive, First Floor South San Francisco, California 94080 United States | |
Phone | 650 239 2030 |
Website | sentibio.com |
Stock Details
Ticker Symbol | SNTI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001854270 |
CUSIP Number | 81726A100 |
ISIN Number | US81726A1007 |
Employer ID | 86-2437900 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
Dr. Kanya Rajangam M.D., Ph.D. | President, Head of Research and Development and Chief Medical Officer |
Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board and Independent Director |
Dr. Wilson Wong Ph.D. | Scientific Co-Founder and Member of Scientific Advisory Board |
Yvonne Li M.B.A. | Interim Chief Financial Officer, Treasurer and Principal Accounting Officer |
Thomas P. Chung | Vice President of Strategic Finance and Corporate Development |
Dee Olomajeye Dragon | Vice President of People Strategy and Culture |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 27, 2024 | 8-K | Current Report |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Jul 17, 2024 | 8-K | Current Report |
Jul 16, 2024 | 8-K | Current Report |
Jul 12, 2024 | 8-K | Current Report |
May 29, 2024 | ARS | Filing |
May 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
May 29, 2024 | DEF 14A | Other definitive proxy statements |
May 17, 2024 | PRE 14A | Other preliminary proxy statements |